![Kate Heffernan](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3285092/affe203d-1927-4185-8e6d-05878f3cba75/profile.png)
Kate Heffernan
USA Guide 2024
Band 2 : Healthcare
Band 2
About
Provided by Kate Heffernan
Practice Areas
When academic medical centers, hospitals, universities, research institutes, start-up biotechnology companies, and other research stakeholders need advice on a comprehensive range of issues affecting biomedical research, they turn to attorney Kate Gallin Heffernan.
Kate counsels clients on issues related to human subjects protection; research noncompliance and misconduct proceedings; research affiliations and contracting; investigator and institutional conflicts of interest; repositories for data, genomic, and tissue research; and the downstream uses of stored materials. She also counsels clients in FDA requirements for clinical investigations and treatment with investigational products pursuant to FDA’s expanded access program and “Right to Try” laws.
In addition to her research-focused practice, Kate advises clients on general patient care issues, including clinical informed consent and the protection of sensitive health information, as well as organ donation and transplantation.
https://www.ebglaw.com/people/kate-gallin-heffernan/
Discover other Lawyers at
Epstein Becker & Green PC
California
Connecticut
![Deborah Cannavino](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3298179/762848ef-9a9c-449f-9d19-ad59caa5663d/profile.png)
![Peter Stein](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3298129/c5962faa-033a-4411-b6d7-242b8bf1445f/profile.png)
![Elizabeth Torkelsen](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3298190/ae05e17e-d599-4c6d-bad2-9b5e849ead36/profile.png)
District of Columbia
![David Matyas](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3275715/c88ff154-ae8b-4709-b317-a0cdabff49f3/profile.png)
![Lynn Shapiro Snyder](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3275714/1437276c-b829-4b20-b619-4cac4dae5554/profile.png)
![Mark Lutes](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3275814/404d42b0-5b5c-4ea1-b41b-9e4400fe42b2/profile.png)
![Carrie Valiant](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3275721/1f696bbb-3b78-4f5a-98c8-a40f4acf02d6/profile.png)
![George Breen](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3275903/1d51eef9-bb56-4d54-8dab-6cded26920ea/profile.png)
![Amy Lerman](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3275884/786ff0d4-e423-4249-9090-8c6ad431e1ee/profile.png)
![Anjali Downs](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3282618/df353926-8528-4773-bce1-85ff266f461d/profile.png)
![Alan Arville](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3276015/16b78321-7575-4746-a605-804a2c3ba6a7/profile.png)
![Paul DeCamp](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3281404/f8d9c321-3a57-4995-9f4a-396f8bb6960f/profile.png)
![Frank Morris](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3281390/b5fe173a-ee12-4939-9b11-93fc995ec162/profile.png)
![Nathaniel Glasser](https://assets-cdn.chambers.com/cdn-cgi/image/format=auto,fit=scale-down/https://media.chambers.com/individuals/3281416/67b29e3f-4f38-4ebc-8956-d906d178e877/profile.png)